Search

Your search keyword '"Schwartz, Gregory G"' showing total 187 results

Search Constraints

Start Over You searched for: Author "Schwartz, Gregory G" Remove constraint Author: "Schwartz, Gregory G" Database Unpaywall Remove constraint Database: Unpaywall
187 results on '"Schwartz, Gregory G"'

Search Results

1. Contributors

4. Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation

6. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES

7. Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES

8. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

9. Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention

10. Impact of age on the predictive value of NT-proBNP in patients with diabetes mellitus stabilised after an acute coronary syndrome

11. Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis

14. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests

16. Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome

17. LIPOPROTEIN(A) AND CARDIOVASCULAR OUTCOMES IN WOMEN AND MEN AFTER AN ACUTE CORONARY SYNDROME: A POST HOC ODYSSEY OUTCOMES TRIAL ANALYSIS

18. EFFICACY AND SAFETY OF INCLISIRAN BY BASELINE BODY MASS INDEX: A POST HOC POOLED ANALYSIS OF THE ORION-9, ORION-10 AND ORION-11 PHASE III RANDOMIZED CONTROLLED TRIALS

19. SHORT-DURATION, VERY HIGH-INTENSITY LIPID-LOWERING THERAPY RESULTS IN PROLONGED REDUCTION OF CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROME

20. POOLED SAFETY ANALYSIS OF INCLISIRAN IN 3,576 PATIENTS WITH APPROXIMATELY 10,000 PERSON YEARS OF EXPOSURE FROM 7 TRIALS

21. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials

22. Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab

23. Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar

24. Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES

25. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes

26. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

27. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

28. Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial

32. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

33. THE EPIGENETIC BET-INHIBITOR APABETALONE REDUCES CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES, ACUTE CORONARY SYNDROME AND AN ELEVATED ANGULO NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE - EXPLORATORY ANALYSIS OF THE BETONMACE TRIAL

35. Contributors

36. Abstract 11033: Efficacy and Safety of Inclisiran by Baseline Glycemic Status: A Post Hoc Pooled Analysis of the ORION-10 and ORION-11 Phase III Randomized Controlled Trials

38. Abstract 11143: Efficacy and Safety of Inclisiran by Baseline Body Mass Index: A Post Hoc Pooled Analysis of the ORION-9, ORION-10 and ORION-11 Phase III Randomized Controlled Trials

39. Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial

41. Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial

42. EFFICACY AND SAFETY OF INCLISIRAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE - A POOLED ANALYSIS FROM THREE PHASE 3 CLINICAL TRIALS (ORION-9, -10 AND -11)

43. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

44. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

45. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

49. Contributing Authors

Catalog

Books, media, physical & digital resources